-
Article
Open AccessInfluence of corticosteroid treatment on CXCR4 expression in DLBCL
CXCR4-targeted radioligand therapy (RLT) with [177Lu]Lu/[90Y]Y-PentixaTher has recently evolved as a promising therapeutic option for patients with advanced hematological cancers. Given their advanced disease sta...
-
Article
Open AccessComparison of absorbed dose extrapolation methods for mouse-to-human translation of radiolabelled macromolecules
Extrapolation of human absorbed doses (ADs) from biodistribution experiments on laboratory animals is used to predict the efficacy and toxicity profiles of new radiopharmaceuticals. Comparative studies between...
-
Article
Correction to: Preclinical Evaluation and Dosimetry of [111In] CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1)
In the original article, some numerical values in the following paragraph were reported incorrectly.
-
Article
Open AccessPreclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1)
Endosialin/tumor endothelial marker-1 (TEM1) is an attractive theranostic target expressed by the microenvironment of a wide range of tumors, as well as by sarcoma and neuroblastoma cells. We report on the rad...
-
Article
Open AccessInternal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice
Biodistribution studies based on organ harvesting represent the gold standard pre-clinical technique for dose extrapolations. However, sequential imaging is becoming increasingly popular as it allows the extra...
-
Article
Open AccessFirst in-human radiation dosimetry of 68Ga-NODAGA-RGDyK
Integrin-targeting radiopharmaceuticals have potential broad applications, spanning from cancer theranostics to cardiovascular diseases. We have previously reported preclinical dosimetry results of 68Ga-NODAGA-RG...
-
Article
Open AccessAntitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia
The increasing availability of different monoclonal antibodies (mAbs) opens the way to more specific biologic therapy of cancer patients. However, despite the significant success of therapy in breast and ovari...
